Glucocorticoids and Mineralocorticoids

Cardiovascular Hormone Systems

Volumn , Issue , 2009, Pages 1-37

  Craigie, Eilidh ^a   Mullins, John J ^a   Bailey, Matthew A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

11 hydroxysteroid dehydrogenase; Aldosterone; Cardiovascular effect; Glucocorticoid; Mineralocorticoid; Steroid receptor

Indexed keywords

EID: 84889339995     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626236.ch1     Document Type: Chapter

References (177)

1. Clark, B.J., Wells, J., King, S.R. and Stocco, D.M. (1994) The purification, cloning, and expression of a novel luteinizing hormone-induced mitochondrial protein in MA-10 mouse Leydig tumor cells. Characterization of the steroidogenic acute regulatory protein (stAR). Journal of Biological Chemistry, 269, 28314-22.
2. Lin, D., Sugawara, T., Strauss, J.F., 3rd, Clark, B.J., Stocco, D.M., Saenger, P., Rogol, A. and Miller, W.L. (1995) Role of steroidogenic acute regulatory protein in adrenal and gonadal steroidogenesis. Science, 267, 1828-31.
3. Stocco, D.M. (2002) Clinical disorders associated with abnormal cholesterol transport: mutations in the steroidogenic acute regulatory protein. Molecular and Cellular Endocrinology, 191, 19-25.
4. Caron, K.M., Soo, S.C., Wetsel, W.C., Stocco, D.M., Clark, B.J. and Parker, K.L. (1997) Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America, 94, 11540-5.
5. Bhangoo, A., Anhalt, H., Ten, S. and King, S.R. (2006) Phenotypic variations in lipoid congenital adrenal hyperplasia. Pediatric Endocrinology Reviews, 3, 258-71.
6. Lifton, R.P., Dluhy, R.G., Powers, M., Rich, G.M., Cook, S., Ulick, S. and Lalouel, J.M. (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension . Nature, 355, 262-5.
7. Gotoh, H., Sagai, T., Hata, J., Shiroishi, T. and Moriwaki, K. (1988) Steroid 21-hydroxylase defi ciency in mice. Endocrinology, 123, 1923-7.
8. Riepe, F.G., Tatzel, S., Sippell, W.G., Pleiss, J. and Krone, N. (2005) Congenital adrenal hyperplasia: the molecular basis of 21-hydroxylase defi ciency in H-2(aw18) mice. Endocrinology, 146, 2563-74.
9. White, P.C., Curnow, K.M. and Pascoe, L. (1994) Disorders of steroid 11 beta-hydroxylase isozymes. Endocrine Reviews, 15, 421-38.
10. Lee, G., Makhanova, N., Caron, K., Lopez, M.L., Gomez, R.A., Smithies, O. and Kim, H.S. (2005) Homeostatic responses in the adrenal cortex to the absence of aldosterone in mice. Endocrinology, 146, 2650-6.
11. Makhanova, N., Lee, G., Takahashi, N., Sequeira Lopez, M.L., Gomez, R.A., Kim, H.S. and Smithies, O. (2006) Kidney function in mice lacking aldosterone. American Journal of Physiology-Renal Physiology, 290, F61-69.
12. Quinn, S.J. and Williams, G.H. (1988) Regulation of aldosterone secretion. Annual Review of Physiology, 50, 409-26.
13. Heffelfi nger, S.C. (2007) The renin angiotensin system in the regulation of angiogenesis. Current Pharmaceutical Design, 13, 1215-29.
14. Kramer, R.E., Gallant, S. and Brownie, A.C. (1980) Actions of angiotensin II on aldosterone biosynthesis in the rat adrenal cortex. Effects on cytochrome P-450 enzymes of the early and late pathway. Journal of Biological Chemistry, 255, 3442-7.
15. Lazartigues, E., Feng, Y. and Lavoie, J.L. (2007) The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases. Current Pharmaceutical Design, 13, 1231-45.
16. Stojiljkovic, L. and Behnia, R. (2007) Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Current Pharmaceutical Design, 13, 1335-45.
17. Hamming, I., Cooper, M.E., Haagmans, B.L., Hooper, N.M., Korstanje, R., Osterhaus, A.D., Timens, W., Turner, A.J. and Navis G., and van Goor, H. (2007) The emerging role of ACE2 in physiology and disease. Journal of Pathology, 212, 1-11.
18. Van Tassell, B.W. and Munger, M.A. (2007) Aliskiren for renin inhibition: a new class of antihypertensives. Annals of Pharmacotherapy, 41, 456-64.
19. Mullins, L.J., Bailey, M.A. and Mullins, J.J. (2006) Hypertension, kidney, and transgenics: a fresh perspective. Physiological Reviews, 86, 709-46.
20. Young, D.B. (1985) Analysis of long-term potassium regulation. Endocrine Reviews, 6, 24-44.
21. Cowley, A.W. and McCaa, R.E. (1976) Acute and chronic dose-response relationships for angiotensin, aldosterone, and arterial pressure at varying levels of sodium intake. Circulation Research, 39, 788-97.
22. Muglia, L.J., Bethin, K.E., Jacobson, L., Vogt, S.K. and Majzoub, J.A. (2000) Pituitary-adrenal axis regulation in CRH-defi cient mice. Endocrine Research, 26, 1057-66.
23. Turnbull, A.V., Smith, G.W., Lee, S., Vale, W.W., Lee, K.F. and Rivier, C. (1999) CRF type I receptor-defi cient mice exhibit a pronounced pituitary-adrenal response to local infl ammation. Endocrinology, 140, 1013-7.
24. Bale, T.L., Picetti, R., Contarino, A., Koob, G.F., Vale, W.W. and Lee, K.F. (2002) Mice defi cient for both corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 have an impaired stress response and display sexually dichotomous anxiety-like behavior. Journal of Neuroscience, 22, 193-9.
25. Makara, G.B., Mergl, Z. and Zelena, D. (2004) The role of vasopressin in hypothalamo-pituitary-adrenal axis activation during stress: an assessment of the evidence. Annals of the New York Academy of Sciences, 1018, 151-61.
26. Lolait, S.J., Stewart, L.Q., Jessop, D.S., Young, W.S., 3rd and O' Carroll, A.M. (2007) The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology, 148, 849-56.
27. Phillips, M.I. (1987) Functions of angiotensin in the central nervous system. Annual Review of Physiology, 49, 413-35.
28. Jezova, D., Makatsori, A., Smriga, M., Morinaga, Y. and Duncko, R. (2005) Subchronic treatment with amino acid mixture of L-lysine and L-arginine modifi es neuroendocrine activation during psychosocial stress in subjects with high trait anxiety. Nutritional Neuroscience, 8, 155-60.
29. Elias, L.L. and Clark, A.J. (2000) The expression of the ACTH receptor. Brazilian Journal of Medical and Biological Research, 33, 1245-8.
30. Wu, S.M., Stratakis, C.A., Chan, C.H., Hallermeier, K.M., Bourdony, C.J., Rennert, O.M. and Chan, W.Y. (1998) Genetic heterogeneity of adrenocorticotropin (ACTH) resistance syndromes: identifi cation of a novel mutation of the ACTH receptor gene in hereditary glucocorticoid defi ciency. Molecular Genetics and Metabolism, 64, 256-65.
31. Lachelin, G.C., Barnett, M., Hopper, B.R., Brink, G. and Yen, S.S. (1979) Adrenal function in normal women and women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 49, 892-8.
32. Schulte, H.M., Chrousos, G.P., Gold, P.W., Booth, J.D., Oldfi eld, E.H., Cutler, G.B., Jr and Loriaux, D.L. (1985) Continuous administration of synthetic ovine corticotropin-releasing factor in man. Physiological and pathophysiological implications. Journal of Clinical Investigation, 75, 1781-5.
33. Sherman, B., Wysham, C. and Pfohl, B. (1985) Age-related changes in the circadian rhythm of plasma cortisol in man. Journal of Clinical Endocrinology and Metabolism, 61, 439-43.
34. Balsalobre, A., Brown, S.A., Marcacci, L., Tronche, F., Kellendonk, C., Reichardt, H.M., Schutz, G. and Schibler, U. (2000) Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science, 289, 2344-7.
35. Howell, M.P. and Muglia, L.J. (2006) Effects of genetically altered brain glucocorticoid receptor action on behavior and adrenal axis regulation in mice. Frontiers in Neuroendocrinology, 27, 275-84.
36. Giles, T.D. (2006) Circadian rhythm of blood pressure and the relation to cardiovascular events. Journal of Hypertension. Supplement, 24, S11-16.
37. Rosmond, R., Chagnon, Y.C., Chagnon, M., Perusse, L., Bouchard, C. and Bjorntorp, P. (2000) A polymorphism of the 5 ′-fl anking region of the gluco corticoid receptor gene locus is associated with basal cortisol secretion in men. Metabolism, 49, 1197-9.
38. Lu, N.Z., Wardell, S.E., Burnstein, K.L., Defranco, D., Fuller, P.J., Giguere, V., Hochberg, R.B., McKay, L., Renoir, J.M., Weigel, N.L. et al. (2006) International Union of Pharmacology. LXV. The pharmacology and classifi cation of the nuclear receptor super family: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacological Reviews, 58, 782-97.
39. Arriza, J.L., Weinberger, C., Cerelli, G., Glaser, T.M., Handelin, B.L., Housman, D.E. and Evans, R.M. (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science, 237, 268-75.
40. Nishi, M. and Kawata, M. (2007) Dynamics of glucocorticoid receptor and mineralocorticoid receptor: implications from live cell imaging studies. Neuroendocrinology, 85, 186-92.
41. Bamberger, C.M., Schulte, H.M. and Chrousos, G.P. (1996) Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Reviews, 17, 245-61.
42. Seckl, J.R. and Walker, B.R. (2004) 11Beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory. Trends in Endocrinology and Metabolism, 15, 418-24.
43. Brown, R.W., Diaz, R., Robson, A.C., Kotelevtsev, Y.V., Mullins, J.J., Kaufman, M.H. and Seckl, J.R. (1996) The ontogeny of 11 beta-hydroxysteroid dehydrogenase type 2 and mineralocorticoid receptor gene expression reveal intricate control of glucocorticoid action in development. Endocrinology, 137, 794-7.
44. Thompson, A., Han, V.K. and Yang, K. (2002) Spatial and temporal patterns of expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 messenger RNA and glucocorticoid receptor protein in the murine placenta and uterus during late pregnancy. Biology of Reproduction, 67, 1708-18.
45. Thompson, A., Han, V.K. and Yang, K. (2004) Differential expression of 11beta-hydroxysteroid dehydrogenase types 1 and 2 mRNA and glucocorticoid receptor protein during mouse embryonic development. Journal of Steroid Biochemistry and Molecular Biology, 88, 367-75.
46. Christy, C., Hadoke, P.W., Paterson, J.M., Mullins, J.J., Seckl, J.R. and Walker, B.R. (2003) 11Beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and infl uence on response to glucocorticoids . Hypertension, 42, 580-7.
47. Agarwal, A.K., Monder, C., Eckstein, B. and White, P.C. (1989) Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. Journal of Biological Chemistry, 264, 18939-43.
48. Agarwal, A.K., Rogerson, F.M., Mune, T. and White, P.C. (1995) Analysis of the human gene encoding the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Journal of Steroid Biochemistry and Molecular Biology, 55, 473-9.
49. Grundy, W.N., Bailey, T.L., Elkan, C.P. and Baker, M.E. (1997) Hidden Markov model analysis of motifs in steroid dehydrogenases and their homologs Biochemical and Biophysical Research Communications, 231, 760-6.
50. Paterson, J.M., Seckl, J.R. and Mullins, J.J. (2005) Genetic manipulation of 11beta-hydroxysteroid dehydrogenases in mice. American Journal of Physiology-Regulatory Integrative and Comparative Physiology, 289, R642-52.
51. Naray-Fejes-Toth, A. and Fejes-Toth, G. (1996) Subcellular localization of the type 2 11beta-hydroxysteroid dehydrogenase. A green fl uorescent protein study. Journal of Biological Chemistry, 271, 15436-42.
52. Odermatt, A., Arnold, P., Stauffer, A., Frey, B.M. and Frey, F.J. (1999) The N-terminal anchor sequences of 11beta-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. Journal of Biological Chemistry, 274, 28762-70.
53. Maser, E., Volker, B. and Friebertshauser, J. (2002) 11Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry, 41, 2459-65.
54. Gomez-Sanchez, E.P., Ganjam, V., Chen, Y.J., Liu, Y., Clark, S.A. and Gomez-Sanchez, C.E. (2001) The 11beta hydroxysteroid dehydrogenase 2 exists as an inactive dimer. Steroids, 66, 845-8.
55. Paterson, J.M., Holmes, M.C., Kenyon, C.J., Carter, R., Mullins, J.J. and Seckl, J.R. (2007) Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-defi cient mice. Endocrinology, 148, 961-6.
56. Yau, J.L., Noble, J., Kenyon, C.J., Hibberd, C., Kotelevtsev, Y., Mullins, J.J. and Seckl, J.R. (2001) Lack of tissue glucocorticoid reactivation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proceedings of the National Academy of Sciences of the United States of America, 98, 4716-21.
57. Zhang, J., Osslund, T.D., Plant, M.H., Clogston, C.L., Nybo, R.E., Xiong, F., Delaney, J.M. and Jordan, S.R. (2005) Crystal structure of murine 11 beta-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. Biochemistry, 44, 6948-57.
58. Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl, J.R. and Flier, J.S. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science, 294, 2166-70.
59. Masuzaki, H., Yamamoto, H., Kenyon, C.J., Elmquist, J.K., Morton, N.M., Paterson, J.M., Shinyama, H., Sharp, M.G., Fleming, S., Mullins, J.J. et al. (2003) Transgenic amplifi cation of glucocorticoid action in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigation, 112, 83-90.
60. Funder, J.W., Pearce, P.T., Smith, R. and Smith, A.I. (1988) Mineralocorticoid action: target tissue specifi city is enzyme, not receptor, mediated. Science, 242, 583-5.
61. Stewart, P.M., Wallace, A.M., Valentino, R., Burt, D., Shackleton, C.H. and Edwards, C.R. (1987) Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase defi ciency comes of age. Lancet, 2, 821-4.
62. Odermatt, A., Arnold, P. and Frey, F.J. (2001) The intracellular localization of the mineralocorticoid receptor is regulated by 11beta-hydroxysteroid dehydrogenase type 2. Journal of Biological Chemistry, 276, 28484-92.
63. Dave-Sharma, S., Wilson, R.C., Harbison, M.D., Newfi eld, R., Azar, M.R., Krozowski, Z.S., Funder, J.W., Shackleton, C.H., Bradlow, H.L., Wei, J.Q. et al. (1998) Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. Journal of Clinical Endocrinology and Metabolism, 83, 2244-54.
64. Monder, C., Shackleton, C.H., Bradlow, H.L., New, M.I., Stoner, E., Iohan, F. and Lakshmi, V. (1986) The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase defi ciency and some consequences for corticosteroid metabolism. Journal of Clinical Endocrinology and Metabolism, 63, 550-7.
65. Morineau, G., Sulmont, V., Salomon, R., Fiquet-Kempf, B., Jeunemaitre, X., Nicod, J. and Ferrari, P. (2006) Apparent mineralocorticoid excess: report of six new cases and extensive personal experience. Journal of the American Society of Nephrology, 17, 3176-84.
66. New, M.I. and Wilson, R.C. (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proceedings of the National Academy of Sciences of the United States of America, 96, 12790-7.
67. Stewart, P.M., Corrie, J.E., Shackleton, C.H. and Edwards, C.R. (1988) Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. Journal of Clinical Investigation, 82, 340-9.
68. Atanasov, A.G., Ignatova, I.D., Nashev, L.G., Dick, B., Ferrari, P., Frey, F.J. and Odermatt, A. (2007) Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Journal of the American Society of Nephrology, 18, 1262-70.
69. Milford, D.V. (1999) Investigation of hypertension and the recognition of monogenic hypertension. Archives of Disease in Childhood, 81, 452-5.
70. Kotelevtsev, Y., Brown, R.W., Fleming, S., Kenyon, C., Edwards, C.R., Seckl, J.R. and Mullins, J.J. (1999) Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. Journal of Clinical Investigation, 103, 683-9.
71. Bailey, M.A., Paterson, J.M., Hadoke, P.W., Wrobel, N., Bellamy, C.O., Brownstein, D.G., Seckl, J.R. and Mullins, J.J. (2008) Switch from sodium-dependent to sodium-indepen dent hypertension in the syndrome of apparent mineralocorticoid excess. Journal of the American Society of Nephrology, 19, 47-58.
72. Palermo, M., Delitala, G., Sorba, G., Cossu, M., Satta, R., Tedde, R., Pala, A. and Shackleton, C.H. (2000) Does kidney transplantation normalise cortisol metabolism in apparent mineralocorticoid excess syndrome?. Journal of Endocrinological Investigation, 23, 457-62.
73. Robson, A.C., Leckie, C.M., Seckl, J.R. and Holmes, M.C. (1998) 11 Beta-hydroxysteroid dehydrogenase type 2 in the postnatal and adult rat brain. Brain Research. Molecular Brain Research, 61, 1-10.
74. Roland, B.L., Li, K.X. and Funder, J.W. (1995) Hybridization histochemical localization of 11 beta-hydroxysteroid dehydrogenase type 2 in rat brain. Endocrinology, 136, 4697-700.
75. Gomez-Sanchez, E.P. (1986) Intracerebroventricular infusion of aldosterone induces hypertension in rats. Endocrinology, 118, 819-23.
76. Gomez-Sanchez, E.P. and Gomez-Sanchez, C.E. (1992) Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. American Journal of Physiology, 263, E1125-1130.
77. Hatakeyama, H., Inaba, S., Takeda, R. and Miyamori, I. (2000) 11Beta-hydroxysteroid dehydrogenase in human vascular cells. Kidney International, 57, 1352-7.
78. Souness, G.W., Brem, A.S. and Morris, D.J. (2002) 11Beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids, 67, 195-201.
79. Walker, B.R., Connacher, A.A., Webb, D.J. and Edwards, C.R. (1992) Glucocorticoids and blood pressure: a role for the cortisol/cortisone shuttle in the control of vascular tone in man. Clinical Science (London), 83, 171-8.
80. Hadoke, P.W., Christy, C., Kotelevtsev, Y.V., Williams, B.C., Kenyon, C.J., Seckl, J.R., Mullins, J.J. and Walker, B.R. (2001) Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase . Circulation, 104, 2832-7.
81. Seckl, J.R. and Holmes, M.C. (2007) Mechanisms of disease: glucocorticoids, their placental metabolism and fetal "programming" of adult pathophysiology. Nature Clinical Practice. Endocrinology & Metabolism, 3, 479-88.
82. Bocchi, B., Kenouch, S., Lamarre-Cliche, M., Muffat-Joly, M., Capron, M.H., Fiet, J., Morineau, G., Azizi, M., Bonvalet, J.P. and Farman, N. (2004) Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension, 43, 803-8.
83. Melander, O., Frandsen, E., Groop, L. and Hulthen, U.L. (2003) No evidence of a relation between 11beta-hydroxysteroid dehydrogenase type 2 activity and salt sensitivity. American Journal of Hypertension, 16, 729-33.
84. Poch, E., Gonzalez, D., Giner, V., Bragulat, E. and Coca A., and de La Sierra, A. (2001) Molecular basis of salt sensitivity in human hypertension. Evaluation of renin-angiotensin-aldosterone system gene polymorphisms. Hypertension, 38, 1204-9.
85. Williams, T.A., Mulatero, P., Filigheddu, F., Troffa, C., Milan, A., Argiolas, G., Parpaglia, P.P., Veglio, F. and Glorioso, N. (2005) Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International, 67, 631-7.
86. Booth, R.E., Johnson, J.P. and Stockand, J.D. (2002) Aldosterone. Advances in Physiology Education, 26, 8-20.
87. Good, D.W. (2007) Nongenomic actions of aldosterone on the renal tubule. Hypertension, 49, 728-39.
88. Campese, V.M. and Park, J. (2006) The kidney and hypertension: over 70 years of research. Journal of Nephrology, 19, 691-8.
89. Young, M.J., Lam, E.Y. and Rickard, A.J. (2007) Mineralocorticoid receptor activation and cardiac fi brosis. Clinical Science, 112, 467-75.
90. Gomez-Sanchez, E.P. (1997) Central hypertensive effects of aldosterone. Frontiers in Neuroendocrinology, 18, 440-62.
91. Levy, D.G., Rocha, R. and Funder, J.W. (2004) Distinguishing the antihypertensive and electrolyte effects of eplerenone. Journal of Clinical Endocrinology and Metabolism, 89, 2736-40.
92. Grossmann, C., Benesic, A., Krug, A.W., Freudinger, R., Mildenberger, S., Gassner, B. and Gekle, M. (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Molecular Endocrinology, 19, 1697-710.
93. Funder, J.W. (2006) Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects. Endocrinology, 147, 5564-7.
94. Brilla, C.G. and Weber, K.T. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fi brosis. Journal of Laboratory and Clinical Medicine, 120, 893-901.
95. Sato, A. and Saruta, T. (2004) Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertension Research, 27, 303-10.
96. Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J. and Gatlin, M. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New England Journal of Medicine, 348, 1309-21.
97. Pitt, B., Zannad, F., Remme, W.J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341, 709-17.
98. Rocha, R. and Funder, J.W. (2002) The pathophysiology of aldosterone in the cardiovascular system. Annals of the New York Academy of Sciences, 970, 89-100.
99. Swedberg, K., Eneroth, P., Kjekshus, J. and Wilhelmsen, L. (1990) Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulationation, 82, 1730-6.
100. Nagata, K., Obata, K., Xu, J., Ichihara, S., Noda, A., Kimata, H., Kato, T., Izawa, H., Murohara, T. and Yokota, M. (2006) Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension, 47, 656-64.
101. Le Menuet, D., Isnard, R., Bichara, M., Viengchareun, S., Muffat-Joly, M., Walker, F., Zennaro, M.C. and Lombes, M. (2001) Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor. Journal of Biological Chemistry, 276, 38911-20.
102. Qin, W., Rudolph, A.E., Bond, B.R., Rocha, R., Blomme, E.A., Goellner, J.J., Funder, J.W. and McMahon, E.G. (2003) Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circulation Research, 93, 69-76.
103. Beggah, A.T., Escoubet, B., Puttini, S., Cailmail, S., Delage, V., Ouvrard-Pascaud, A., Bocchi, B., Peuchmaur, M., Delcayre, C., Farman, N. et al. (2002) Reversible cardiac fi brosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America, 99, 7160-5.
104. Funder, J.W. (2004) Is aldosterone bad for the heart?. Trends in Endocrinology and Metabolism, 15, 139-42.
105. Funder, J.W. (2005) RALES, EPHESUS and redox. Journal of Steroid Biochemistry and Molecular Biology, 93, 121-5.
106. Mihailidou, A.S. and Funder, J.W. (2005) Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids, 70, 347-51.
107. Duprez, D.A. (2007) Aldosterone and the vasculature: mechanisms mediating resistant hypertension. Journal of Clinical Hypertension (Greenwich), 9, 13-8.
108. Cai, T.Q., Wong, B., Mundt, S.S., Thieringer, R., Wright, S.D. and Hermanowski-Vosatka, A. (2001) Induction of 11beta-hydroxysteroid dehydrogenase type 1 but not-2 in human aortic smooth muscle cells by infl ammatory stimuli. Journal of Steroid Biochemistry and Molecular Biology, 77, 117-22.
109. Hatakeyama, H., Inaba, S. and Miyamori, I. (1999) 11Beta-hydroxysteroid dehydrogenase in cultured human vascular cells. Possible role in the development of hypertension. Hypertension, 33, 1179-84.
110. Brem, A.S., Bina, R.B., King, T.C. and Morris, D.J. (1998) Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension, 31, 459-62.
111. Ullian, M.E. (1999) The role of corticosteriods in the regulation of vascular tone. Cardiovascular Research, 41, 55-64.
112. Couture, R. and Regoli, D. (1980) Vascular reactivity to angiotensin and noradrenaline in rats maintained on a sodium free diet or made hypertensive with desoxycorticosterone acetate and salt (DOCA/salt). Clinical and Experimental Hypertension, 2, 25-43.
113. White, R.E. and Carrier, G.O. (1986) Alpha 1-and alpha 2-adrenoceptor agonist-induced contraction in rat mesenteric artery upon removal of endothelium. European Journal of Pharmacology, 122, 349-52.
114. Ullian, M.E. and Fine, J.J. (1994) Mechanisms of enhanced angiotensin II-stimulated signal transduction in vascular smooth muscle by aldosterone. Journal of Cellular Physiology, 161, 201-8.
115. Schelling, J.R., DeLuca, D.J., Konieczkowski, M., Marzec, R., Sedor, J.R., Dubyak, G.R. and Linas, S.L. (1994) Glucocorticoid uncoupling of antiogensin II-dependent phospholipase C activation in rat vascular smooth muscle cells. Kidney International, 46, 675-82.
116. Uno, S., Guo, D.F., Nakajima, M., Ohi, H., Imada, T., Hiramatsu, R., Nakakubo, H., Nakamura, N. and Inagami, T. (1994) Glucocorticoid induction of rat angiotensin II type 1A receptor gene promoter. Biochemical and Biophysical Research Communications, 204, 210-5.
117. Chan, J.S., Ming, M., Nie, Z.R., Sikstrom, R., Lachance, S. and Carriere, S. (1992) Hormonal regulation of expression of the angiotensinogen gene in cultured opossum kidney proximal tubular cells. Journal of the American Society of Nephrology, 2, 1516-22.
118. Sim, M.K. and Chan, C.S. (1992) Effect of experimentally-induced hypertension on angiotensin converting enzyme activity in the aortic endothelium and smooth muscle cum adventitia of the Sprague Dawley rat. Life Sciences, 50, 1821-5.
119. Meggs, L.G., Stitzel, R., Ben-Ari, J., Chander, P., Gammon, D., Goodman, A.I. and Head, R. (1988) Upregulation of the vascular alpha-1 receptor in malignant DOCA-salt hypertension. Clinical and Experimental Hypertension A., 10, 229-47.
120. Haigh, R.M. and Jones, C.T. (1990) Effect of glucocorticoids on alpha 1-adrenergic receptor binding in rat vascular smooth muscle. Journal of Molecular Endocrinology, 5, 41-8.
121. Longhurst, P.A., Rice, P.J., Taylor, D.A. and Fleming, W.W. (1988) Sensitivity of caudal arteries and the mesenteric vascular bed to norepinephrine in DOCA-salt hypertension. Hypertension, 12, 133-42.
122. Lockette, W., Otsuka, Y. and Carretero, O. (1986) The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension, 8, II61-66.
123. Handa, M., Kondo, K., Suzuki, H. and Saruta, T. (1984) Dexamethasone hypertension in rats: role of prostaglandins and pressor sensitivity to norepinephrine. Hypertension, 6, 236-41.
124. Losel, R., Schultz, A., Boldyreff, B. and Wehling, M. (2004) Rapid effects of aldosterone on vascular cells: clinical implications. Steroids, 69, 575-8.
125. Schmidt, B.M., Oehmer, S., Delles, C., Bratke, R., Schneider, M.P., Klingbeil, A., Fleischmann, E.H. and Schmieder, R.E. (2003) Rapid nongenomic effects of aldosterone on human forearm vasculature. Hypertension, 42, 156-60.
126. Schmidt, B.M., Sammer, U., Fleischmann , I., Schlaich, M., Delles, C. and Schmieder, R.E. (2006) Rapid nongenomic effects of aldosterone on the renal vasculature in humans. Hypertension , 47, 650-5.
127. Yee, K.M. and Struthers, A.D. (1998) Aldosterone blunts the barorefl ex response in man. Clinical Science (London, England), 95, 687-92.
128. Schiffrin, E.L., Lariviere, R., Li, J.S., Sventek, P. and Touyz, R.M. (1995) Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension, 25, 769-73.
129. Landmesser, U., Hornig, B. and Drexler, H. (2004) Endothelial function: a critical determinant in atherosclerosis? Circulation, 109, II27-33.
130. Oberleithner, H. (2005) Aldosterone makes human endothelium stiff and vulnerable. Kidney International, 67, 1680-2.
131. Nietlispach, F., Julius, B., Schindler, R., Bernheim, A., Binkert, C., Kiowski, W. and Brunner-La Rocca, H.P. (2007) Infl uence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension, 50, 82-8.
132. Williams, G.H. (2005) Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Failure Reviews, 10, 7-13.
133. Savoia, C. and Schiffrin, E.L. (2006) Infl ammation in hypertension. Current Opinion in Nephrology and Hypertension, 15, 152-8.
134. Kathiresan, S., Larson, M.G., Benjamin, E.J., Corey, D., Murabito, J.M., Fox, C.S., Wilson, P.W., Rifai, N., Meigs, J.B., Ricken, G. et al. (2005) Clinical and genetic correlates of serum aldosterone in the community: the Framingham Heart Study. American Journal of Hypertension, 18, 657-65.
135. Berger, S., Bleich, M., Schmid, W., Cole, T.J., Peters, J., Watanabe, H., Kriz, W., Warth, R., Greger, R. and Schutz, G. (1998) Mineralocorticoid receptor knockout mice: pathophysiology of Na + metabolism. Proceedings of the National Academy of Sciences of the United States of America, 95, 9424-9.
136. Berger, S., Wolfer, D.P., Selbach, O., Alter, H., Erdmann, G., Reichardt, H.M., Chepkova, A.N., Welzl, H., Haas, H.L., Lipp, H.P. et al. (2006) Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. Proceedings of the National Academy of Sciences of the United States of America, 103, 195-200.
137. Ronzaud, C., Loffi ng, J., Bleich, M., Gretz, N., Grone, H.J., Schutz, G. and Berger, S. (2007) Impairment of sodium balance in mice defi cient in renal principal cell mineralocorticoid receptor. Journal of the American Society of Nephrology, 18, 1679-87.
138. Girod, J.P. and Brotman, D.J. (2004) Does altered glucocorticoid homeostasis increase cardiovascular risk? Cardiovascular Research, 64, 217-26.
139. Hammer, F. and Stewart, P.M. (2006) Cortisol metabolism in hypertension. Best Practice and Research Clinical Endocrinology and Metabolism, 20, 337-53.
140. Wintermantel, T.M., Berger, S., Greiner, E.F. and Schutz, G. (2005) Evaluation of steroid receptor function by gene targeting in mice. Journal of Steroid Biochemistry and Molecular Biology, 93, 107-12.
141. Cole, T.J., Blendy, J.A., Monaghan, A.P., Krieglstein, K., Schmid, W., Aguzzi, A., Fantuzzi, G., Hummler, E., Unsicker, K. and Schutz, G. (1995) Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffi n cell development and severely retards lung maturation. Genes and Development, 9, 1608-21.
142. Kellendonk, C., Tronche, F., Reichardt, H.M. and Schutz, G. (1999) Mutagenesis of the glucocorticoid receptor in mice. Journal of Steroid Biochemistry and Molecular Biology, 69, 253-9.
143. Reichardt, H.M., Kaestner, K.H., Tuckermann, J., Kretz, O., Wessely, O., Bock, R., Gass, P., Schmid, W., Herrlich, P., Angel, P. et al. (1998) DNA binding of the glucocorticoid receptor is not essential for survival. Cell, 93, 531-41.
144. Tronche, F., Opherk, C., Moriggl, R., Kellendonk, C., Reimann, A., Schwake, L., Reichardt, H.M., Stangl, K., Gau, D., Hoefl ich, A. et al. (2004) Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes and Development, 18, 492-7.
145. Tronche, F., Kellendonk, C., Kretz, O., Gass, P., Anlag, K., Orban, P.C., Bock, R., Klein, R. and Schutz, G. (1999) Disruption of the glucocorticoid receptor gene in the nervous system results in reduced anxiety. Nature Genetics, 23, 99-103.
146. Sainte-Marie, Y., Cat, A.N., Perrier, R., Mangin, L., Soukaseum, C., Peuchmaur, M., Tronche, F., Farman, N., Escoubet, B., Benitah, J.P. et al. (2007) Conditional glucocorticoid receptor expression in the heart induces atrio-ventricular block. FASEB Journal, 21, 3133-41.
147. Newell-Price, J., Bertagna, X., Grossman, A.B. and Nieman, L.K. (2006) Cushing' s syndrome. Lancet, 367, 1605-17.
148. Whitworth, J.A., Williamson, P.M., Mangos, G. and Kelly, J.J. (2005) Cardiovascular consequences of cortisol excess. Vascular Health and Risk Management, 1, 291-9.
149. Etxabe, J. and Vazquez, J.A. (1994) Morbidity and mortality in Cushing' s disease: an epidemiological approach. Clinical Endocrinology, 40, 479-84.
150. Arnaldi, G., Mancini, T., Polenta, B. and Boscaro, M. (2004) Cardiovascular risk in Cushing' s syndrome. Pituitary, 7, 253-6.
151. Magiakou, M.A., Smyrnaki, P. and Chrousos, G.P. (2006) Hypertension in Cushing' s syndrome. Best Practice and Research Clinical Endocrinology and Metabolism, 20, 467-82.
152. Birkenhager, A.M. and van den Meiracker, A.H. (2007) Causes and consequences of a non-dipping blood pressure profile. Netherlands Journal of Medicine, 65, 127-31.
153. Aizawa, Y., Kamimura, N., Watanabe, H., Aizawa, Y., Makiyama, Y., Usuda, Y., Watanabe, T. and Kurashina, Y. (2006) Cardiovascular risk factors are really linked in the metabolic syndrome: this phenomenon suggests clustering rather than coincidence. International Journal of Cardiology, 109, 213-8.
154. Chew, G.T., Gan, S.K. and Watts, G.F. (2006) Revisiting the metabolic syndrome. Medical Journal of Australia, 185, 445-9.
155. Grundy, S.M. (2007) Metabolic syndrome: a multiplex cardiovascular risk factor. Journal of Clinical Endocrinology and Metabolism, 92, 399-404.
156. Walker, B.R. (2006) Cortisol-cause and cure for metabolic syndrome?. Diabetic Medicine, 23, 1281-8.
157. Livingstone, D.E., Jones, G.C., Smith, K., Jamieson, P.M., Andrew, R., Kenyon, C.J. and Walker, B.R. (2000) Understanding the role of glucocorticoids in obesity: tissue-specifi c alterations of corticosterone metabolism in obese Zucker rats. Endocrinology, 141, 560-3.
158. Livingstone, D.E., Kenyon, C.J. and Walker, B.R. (2000) Mechanisms of dysregulation of 11 beta-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. Journal of Endocrinology, 167, 533-9.
159. Rask, E., Olsson, T., Soderberg, S., Andrew, R., Livingstone, D.E., Johnson, O. and Walker, B.R. (2001) Tissue-specifi c dysregulation of cortisol metabolism in human obesity. Journal of Clinical Endocrinology and Metabolism, 86, 1418-21.
160. Rask, E., Walker, B.R., Soderberg, S., Livingstone, D.E., Eliasson, M., Johnson, O., Andrew, R. and Olsson, T. (2002) Tissue-specifi c changes in peripheral cortisol metabolism in obese women: increased adipose 11beta-hydroxysteroid dehydrogenase type 1 activity. Journal of Clinical Endocrinology and Metabolism, 87, 3330-6
161. van Rossum, E.F. and Lamberts, S.W. (2006) Glucocorticoid resistance syndrome: a diagnostic and therapeutic approach. Best Practice and Research Clinical Endocrinology and Metabolism, 20, 611-26.
162. Charmandari, E., Kino, T., Souvatzoglou, E., Vottero, A., Bhattacharyya, N. and Chrousos, G.P. (2004) Natural glucocorticoid receptor mutants causing generalized glucocorticoid resistance: molecular genotype, genetic transmission, and clinical phenotype. Journal of Clinical Endocrinology and Metabolism, 89, 1939-49.
163. Chrousos, G.P., Detera-Wadleigh, S.D. and Karl, M. (1993) Syndromes of glucocorticoid resistance. Annals of Internal Medicine, 119, 1113-24.
164. Huizenga, N.A., Koper, J.W., De Lange, P., Pols, H.A., Stolk, R.P., Burger, H., Grobbee, D.E., Brinkmann, A.O., De Jong, F.H. and Lamberts, S.W. (1998) A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. Journal of Clinical Endocrinology and Metabolism, 83, 144-51
165. van Rossum, E.F. and Lamberts, S.W. (2004) Polymorphisms in the glucocorticoid receptor gene and their associations with metabolic parameters and body composition. Recent Progress in Hormone Research, 59, 333-57.
166. Lin, R.C., Wang, X.L. and Morris, B.J. (2003) Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension, 41, 404-7.
167. Murray, J.C., Smith, R.F., Ardinger, H.A. and Weinberger, C. (1987) RFLP for the glucocorticoid receptor (GRL) located at 5q11-5q13. Nucleic Acids Research, 15, 6765.
168. Koper, J.W., Stolk, R.P., de Lange, P., Huizenga, N.A., Molijn, G.J., Pols, H.A., Grobbee, D.E., Karl, M., de Jong, F.H., Brinkmann, A.O. et al. (1997) Lack of association between fi ve polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Human Genetics, 99, 663-8
169. van Rossum, E.F., Feelders, R.A., van den Beld, A.W., Uitterlinden, A.G., Janssen, J.A., Ester, W., Brinkmann, A.O., Grobbee, D.E., de Jong, F.H., Pols, H.A. et al. (2004) Association of the ER22/23EK polymorphism in the glucocorticoid receptor gene with survival and C-reactive protein levels in elderly men. American Journal of Medicine, 117, 158-62
170. van Rossum, E.F., Voorhoeve, P.G., Velde, S.J., Koper, J.W., Delemarre-Van De Waal, H.A., Kemper, H.C. and Lamberts, S.W. (2004) The ER22/23EK polymorphism in the glucocorticoid receptor gene is associated with a benefi cial body composition and muscle strength in young adults. Journal of Clinical Endocrinology and Metabolism, 89, 4004-9.
171. Ross, R. (1999) Atherosclerosis is an infl ammatory disease. American Heart Journal, 138, S419-420.
172. Colao, A., Pivonello, R., Spiezia, S., Faggiano, A., Ferone, D., Filippella, M., Marzullo, P., Cerbone, G., Siciliani, M. and Lombardi, G. (1999) Persistence of increased cardiovascular risk in patients with Cushing' s disease after fi ve years of successful cure. Journal of Clinical Endocrinology and Metabolism, 84, 2664-72.
173. Hermanowski-Vosatka, A., Balkovec, J.M., Cheng, K., Chen, H.Y., Hernandez, M., Koo, G.C., Le Grand, C.B., Li, Z., Metzger, J.M., Mundt, S.S. et al. (2005) 11betaHSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. Journal of Experimental Medicine, 202, 517-27.
174. Del Rincon, I., O' Leary, D.H., Haas, R.W. and Escalante, A. (2004) Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis and Rheumatism, 50, 3813-22.
175. Morton, N.M., Holmes, M.C., Fiévet, C., Staels, B., Tailleux, A., Mullins, J.J., Seckl, J.R. (2001) Improved lipid and lipoprotein profi le, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. Journal of Biological Chemistry, 276, 41293-300.
176. Morton, N.M., Paterson, J.M., Masuzaki, H., Holmes, M.C., Staels, B., Fiévet, C., Walker, B.R., Flier, J.S., Mullins, J.J., Seckl, J.R. (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-defi cient mice. Diabetes, 53, 931-8.
177. Endemann, D.H., Touyz, R.M., Iglarz, M., Savoia, C., Schiffrin, E.L. (2004) Eplerenone prevents salt-induced vascular remodeling and cardiac fi brosis in stroke-prone spontaneously hypertensive rats. Hypertension, 43, 1252-7.